Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120 and keeps an Outperform rating on the shares after the company reported the Phase 2 TOIVA readout for Qtorin rapamycin in cutaneous venous malformations. The firm says 10 of 15 patients presented as “much improved” or “very much improved” over just 12 weeks.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $212 from $122 at Lucid Capital
- Palvella Therapeutics Reports Positive Phase 2 Study Results
- Palvella Therapeutics announces topline results from Phase 2 TOIVA trial
- Positive Buy Rating for Palvella Therapeutics Driven by Promising Developments in DSAP Treatment
- Palvella Therapeutics: Promising Biopharmaceutical Growth with QTORIN Platform Advancements